Format

Send to

Choose Destination
BMC Syst Biol. 2018 Apr 11;12(Suppl 1):11. doi: 10.1186/s12918-018-0534-5.

Regulation of dual specificity phosphatases in breast cancer during initial treatment with Herceptin: a Boolean model analysis.

Author information

1
Department of Molecular Genetics, The Weizmann Institute of Science, Rehovot, Israel.
2
School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
3
School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK. Jean-marc.Schwartz@manchester.ac.uk.

Abstract

BACKGROUND:

25% of breast cancer patients suffer from aggressive HER2-positive tumours that are characterised by overexpression of the HER2 protein or by its increased tyrosine kinase activity. Herceptin is a major drug used to treat HER2 positive breast cancer. Understanding the molecular events that occur when breast cancer cells are exposed to Herceptin is therefore of significant importance. Dual specificity phosphatases (DUSPs) are central regulators of cell signalling that function downstream of HER2, but their role in the cellular response to Herceptin is mostly unknown. This study aims to model the initial effects of Herceptin exposure on DUSPs in HER2-positive breast cancer cells using Boolean modelling.

RESULTS:

We experimentally measured expression time courses of 21 different DUSPs between 0 and 24 h following Herceptin treatment of human MDA-MB-453 HER2-positive breast cancer cells. We clustered these time courses into patterns of similar dynamics over time. In parallel, we built a series of Boolean models representing the known regulatory mechanisms of DUSPs and then demonstrated that the dynamics predicted by the models is in agreement with the experimental data. Furthermore, we used the models to predict regulatory mechanisms of DUSPs, where these mechanisms were partially known.

CONCLUSIONS:

Boolean modelling is a powerful technique to investigate and understand signalling pathways. We obtained an understanding of different regulatory pathways in breast cancer and new insights on how these signalling pathways are activated. This method can be generalized to other drugs and longer time courses to better understand how resistance to drugs develops in cancer cells over time.

KEYWORDS:

Boolean model; Breast cancer; DUSPs; Herceptin

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center